NEWS HIGHLIGHTSMedia Articles Related to Aromasin (Exemestane)
Cost Of Noncompliance Revealed By Study Of Adjuvant Endocrine Treatment For Breast Cancer
Source: Compliance News From Medical News Today [2009.09.23]
The largest study in the world of treatments for post menopausal, hormone positive breast cancer has shown that patients who continue to take exemestane or tamoxifen do significantly better than patients who start to take one or other drug (or tamoxifen followed exemestane) but then stop.
Secretary Sebelius Statement On New Breast Cancer Recommendations
Source: Health News from Medical News Today [2009.11.19]
HHS Secretary Kathleen Sebelius issued the following statement today on new breast cancer screening recommendations from the U.S. Preventive Services Task Force: "There is no question that the U.S. Preventive Services Task Force Recommendations have caused a great deal of confusion and worry among women and their families across this country. I want to address that confusion head on. The U.S.
Breast Cancer Campaign: New Breast Cancer Research Funding For Belfast
Source: Health News from Medical News Today [2009.11.19]
Individualised radiotherapy treatment based on a person's genetic make up could soon become a reality, according to Breast Cancer Campaign. Professor Kevin Prise from Queen's University Belfast has been awarded a three year project grant by the charity to study how genes are involved in the effectiveness of radiotherapy treatment for breast cancer.
Some Physicians Say New Breast Cancer Screening Guidelines Unlikely To Alter Their Practices
Source: Health News from Medical News Today [2009.11.19]
One day after the release of new breast cancer screening guidelines, many physicians and some medical groups are saying that they do not plan to adopt the new recommendations -- which represent a drastic change -- the New York Times reports (Belluck, New York Times, 11/18). The guidelines, released by the U.S.
Radiation Breakthrough Gives Breast Cancer Patients Hope In Single Dose
Source: Breast Cancer News From Medical News Today [2009.11.19]
A radiation breakthrough to treat breast cancer patients in one day, as opposed to the current average of six weeks, has arrived at Cancer Treatment Centers of America(R) (CTCA) in Philadelphia. CTCA will become the first in the country to offer this treatment option using the Novac7 technology from Rome, Italy.
Published Studies Related to Aromasin (Exemestane)
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. [2009.08]
The aim of this study was to evaluate antitumor effects of cyclooxygenase-2 inhibitors in breast carcinoma and their ability to act synergistically with aromatase inhibitors (AIs). Postmenopausal metastatic breast cancer patients without previous adjuvant AI treatment received exemestane 25 mg/days plus either celecoxib 400 mg twice daily or placebo...
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. [2009.07]
BACKGROUND: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss... CONCLUSIONS: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.
The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. [2009.06]
Adjuvant treatment of breast cancer with aromatase inhibitors has been associated with increased bone loss. In this study, postmenopausal patients with oestrogen receptor positive breast cancer were randomised to exemestane for 5 years or tamoxifen for 2-2.5 years, followed by exemestane for 2-2.5 years.
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. [2009.02]
PURPOSE: Patients developing visceral breast cancer metastases generally receive chemotherapy rather than endocrine therapy. Recent aromatase inhibitor studies have reported activity in such patients; therefore, this study formally evaluated anastrozole and exemestane in postmenopausal patients in this setting... CONCLUSION: Efficacy was similar in both treatment groups for all endpoints. Aromatase inhibitors can be considered as a treatment option in postmenopausal patients with hormone receptor-positive visceral breast cancer metastases.
Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. [2009]
BACKGROUND: Previous studies have indicated that a subset of cancer patients treated with chemotherapy show cognitive deficits and/or experience cognitive complaints, whereas literature about the influence of hormonal therapies on cognition is sparse... Future research with larger groups is recommended to obtain a more definite picture.
Clinical Trials Related to Aromasin (Exemestane)
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer [Active, not recruiting]
To compare recurrence free survival between two treatment groups (5 years with exemestane vs
2. 5 to 3 years tamoxifen followed by 2 to 2. 5 years of exemestane for a total duration of 5
years)
Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women [Terminated]
The purpose of this study is to find out if the two different formulations of exemestane
(Aromasin), oral and injectable, are equivalent in terms of pharmacodynamics and
pharmacokinetics, i. e., if ultimately both formulations have the same efficacy in
postmenopausal women with metastatic breast cancer who have failed previous antiestrogens
therapy and are equally safe.
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer [Active, not recruiting]
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin
(exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer.
Patients will be treated until disease progression or until the investigator has determined
that treatment is not in the best interest of the patient, whichever occurs first.
Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer [Active, not recruiting]
Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease [Active, not recruiting]
The purpose of this research study is to learn about the effects of two drugs when they are
given together. The names of the drugs are raloxifene and exemestane.
Raloxifene is a drug that is related to estrogen. In the liver and bone, it acts like
estrogen. In the breast and uterus it acts like an anti-estrogen. It has been used in
postmenopausal women to prevent a disease called osteoporosis. This is a disease that
decreases bone strength over many years and may finally lead to bone fractures. In a group of
women who were taking the drug, it also seemed to decrease the chances of breast cancer and
possibly endometrial cancer (cancer of the uterus). Therefore, we want to study it further to
see if it prevents breast cancer. We also want to find out if it may be even better in
preventing breast cancer if it is given with another drug.
The other drug in this trial is exemestane. Exemestane is a type of drug that works to
decrease estrogen levels in postmenopausal women. This type of drug is used in women for the
treatment of breast cancer. Before we can decide if the two drugs combined are better for
preventing breast cancer, we must first test these drugs together to make sure that they are
safe. This safety testing is the purpose of this trial.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Aromasin has an overall score of 9. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| | Aromasin review by 57 year old female patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Considerably Effective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | Breast Cancer |
| Dosage & duration: | | 5mg taken 1/day for the period of 3 years |
| Other conditions: | | under-active thyroid |
| Other drugs taken: | | Synthroid | | |
Reported Results |
| Benefits: | | Aromasin's treatment benefits are unknown. I have not had a reoccurance of breast cancer while on the drug, though unsure we can attribute that with the drug treatment itself. Perhaps there are other positive health-related items coming into play, such as exerciase and eating habits. Not aware of any side effects or adverse reactions. Drug is very expensive, however. |
| Side effects: | | As mentioned above, I have not had any side effects from Aromasin other than hot flashes and night sweats. These may be due to menopause rather than the treatment itself. The hot flashes have been relatively mild and can be controlled, for the most part, by limiting or removing all alcoholic beverages. |
| Comments: | | After breast cancer treatment of chemo. and radiation I was put on Tamoxifen for several years, about 5 years. After Tamoxifen, it was recommended that I start taking Aromasin, which I have done for about 3 years. My doctor said it is not known how long women should be on Aromasin and still receeve a benefit from taking the drug. |
|
|
